A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Dravet Syndrome

Interventions

DRUG: zorevunersen
OTHER: Sham Comparator

Sponsor

Stoke Therapeutics, Inc